Mucoepidermoid carcinoma of the parotid gland: Twenty-year experience in treatment and outcomes

Stephen A. Chan, Kathryn M. Van Abel, Jean E. Lewis, David M. Routman, Joaquin J. Garcia, Emily E. Karp, Daniel L. Price, Jeffrey R. Janus, Jan L. Kasperbauer, Eric J. Moore

Research output: Contribution to journalArticlepeer-review


Background: Parotid gland mucoepidermoid carcinoma (MEC) has published five-year cancer-specific survival (CSS) rates of 77%–97%, with variance related to grade. Methods: Patients receiving primary surgery for parotid gland MEC from 1995 to 2014 at a tertiary medical center underwent clinical review, histopathologic review, and cytogenetic analysis. Survival outcomes were evaluated. Results: Among 58 patients, T/N/M classification was as follows: T1 in 35 patients, T2 in 14, T4a in 9, N0 in 53, N1 in 2, N2b in 3. Histologic grade was low in 27, intermediate in 17, and high in 12 patients with 98% MAML2 positivity. All patients underwent parotidectomy, and seven patients received adjuvant radiation therapy. CSS was 100% at 5 years and 94.1% at 10 and 15 years. Two patients experienced locoregional recurrence. Conclusions: Treatment with adequate surgical resection and adjuvant radiation therapy for high-grade or advanced-stage tumors yields excellent survival, independent of clinical stage or pathologic grade.

Original languageEnglish (US)
Pages (from-to)2663-2671
Number of pages9
JournalHead and Neck
Issue number9
StatePublished - Sep 2021


  • MAML2
  • mucoepidermoid carcinoma
  • parotid gland
  • parotidectomy
  • salivary gland

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'Mucoepidermoid carcinoma of the parotid gland: Twenty-year experience in treatment and outcomes'. Together they form a unique fingerprint.

Cite this